PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Novel autoantibodies in Sjogren's syndrome.

Abstract Sjogren's syndrome (SS) is defined by autoantibodies to Ro and La. The current studies identified additional autoantibodies in SS to salivary gland protein 1 (SP-1), carbonic anhydrase 6 (CA6) and parotid secretory protein (PSP). These autoantibodies were present in two animal models for SS and occurred earlier in the course of the disease than antibodies to Ro or La. Patients with SS also produced antibodies to SP-1, CA6 and PSP. These antibodies were found in 45% of patients meeting the criteria for SS who lacked antibodies to Ro or La. Furthermore, in patients with idiopathic xerostomia and xerophthalmia for less than 2 years, 76% had antibodies to SP-1 and/or CA6 while only 31% had antibodies to Ro or La. Antibodies to SP-1, CA6 and PSP may be useful markers for identifying patients with SS at early stages of the disease or those that lack antibodies to either Ro or La.
PMID
Related Publications

Anti-salivary gland protein 1 antibodies in two patients with Sjogren's syndrome: two case reports.

Time course of cytokine upregulation in the lacrimal gland and presence of autoantibodies in a predisposed mouse model of Sj?gren's Syndrome: the influence of sex hormones and genetic background.

Discrimination between Sj?gren's and non-Sj?gren's sicca syndrome by sialoscintigraphy and antibodies against alpha-fodrin and Ro/La autoantigens.

Immunization with 60 kD Ro peptide produces different stages of preclinical autoimmunity in a Sj?gren's syndrome model among multiple strains of inbred mice.

Investigation of novel autoantibodies in Sjogren's syndrome utilizing Sera from the Sjogren's international collaborative clinical alliance cohort.

Authors

Mayor MeshTerms
Keywords
Journal Title clinical immunology (orlando, fla.)
Publication Year Start
%A Shen, Long; Suresh, Lakshmanan; Lindemann, Matthew; Xuan, Jingxiu; Kowal, Przemek; Malyavantham, Kishore; Ambrus, Julian L.
%T Novel autoantibodies in Sjogren's syndrome.
%J Clinical immunology (Orlando, Fla.), vol. 145, no. 3, pp. 251-255
%D 12/2012
%V 145
%N 3
%M eng
%B Sjogren's syndrome (SS) is defined by autoantibodies to Ro and La. The current studies identified additional autoantibodies in SS to salivary gland protein 1 (SP-1), carbonic anhydrase 6 (CA6) and parotid secretory protein (PSP). These autoantibodies were present in two animal models for SS and occurred earlier in the course of the disease than antibodies to Ro or La. Patients with SS also produced antibodies to SP-1, CA6 and PSP. These antibodies were found in 45% of patients meeting the criteria for SS who lacked antibodies to Ro or La. Furthermore, in patients with idiopathic xerostomia and xerophthalmia for less than 2 years, 76% had antibodies to SP-1 and/or CA6 while only 31% had antibodies to Ro or La. Antibodies to SP-1, CA6 and PSP may be useful markers for identifying patients with SS at early stages of the disease or those that lack antibodies to either Ro or La.
%K Animals, Antibodies, Antinuclear, Autoantibodies, Autoantigens, Biomarkers, Carbonic Anhydrases, Case-Control Studies, Disease Models, Animal, Disease Progression, Female, Humans, Interleukins, Male, Mice, Mice, Inbred C57BL, Mice, Inbred NOD, Mice, Transgenic, Salivary Proteins and Peptides, Sjogren's Syndrome, Xerophthalmia, Xerostomia
%P 251
%L 255
%Y 10.1016/j.clim.2012.09.013
%W PHY
%G AUTHOR
%R 2012......145..251S

@Article{Shen2012,
author="Shen, Long
and Suresh, Lakshmanan
and Lindemann, Matthew
and Xuan, Jingxiu
and Kowal, Przemek
and Malyavantham, Kishore
and Ambrus, Julian L.",
title="Novel autoantibodies in Sjogren's syndrome.",
journal="Clinical immunology (Orlando, Fla.)",
year="2012",
month="Dec",
day="12",
volume="145",
number="3",
pages="251--255",
keywords="Animals",
keywords="Antibodies, Antinuclear",
keywords="Autoantibodies",
keywords="Autoantigens",
keywords="Biomarkers",
keywords="Carbonic Anhydrases",
keywords="Case-Control Studies",
keywords="Disease Models, Animal",
keywords="Disease Progression",
keywords="Female",
keywords="Humans",
keywords="Interleukins",
keywords="Male",
keywords="Mice",
keywords="Mice, Inbred C57BL",
keywords="Mice, Inbred NOD",
keywords="Mice, Transgenic",
keywords="Salivary Proteins and Peptides",
keywords="Sjogren's Syndrome",
keywords="Xerophthalmia",
keywords="Xerostomia",
abstract="Sjogren's syndrome (SS) is defined by autoantibodies to Ro and La. The current studies identified additional autoantibodies in SS to salivary gland protein 1 (SP-1), carbonic anhydrase 6 (CA6) and parotid secretory protein (PSP). These autoantibodies were present in two animal models for SS and occurred earlier in the course of the disease than antibodies to Ro or La. Patients with SS also produced antibodies to SP-1, CA6 and PSP. These antibodies were found in 45\% of patients meeting the criteria for SS who lacked antibodies to Ro or La. Furthermore, in patients with idiopathic xerostomia and xerophthalmia for less than 2 years, 76\% had antibodies to SP-1 and/or CA6 while only 31\% had antibodies to Ro or La. Antibodies to SP-1, CA6 and PSP may be useful markers for identifying patients with SS at early stages of the disease or those that lack antibodies to either Ro or La.",
issn="1521-7035",
doi="10.1016/j.clim.2012.09.013",
url="http://www.ncbi.nlm.nih.gov/pubmed/23123440",
language="eng"
}

%0 Journal Article
%T Novel autoantibodies in Sjogren's syndrome.
%A Shen, Long
%A Suresh, Lakshmanan
%A Lindemann, Matthew
%A Xuan, Jingxiu
%A Kowal, Przemek
%A Malyavantham, Kishore
%A Ambrus, Julian L.
%J Clinical immunology (Orlando, Fla.)
%D 2012
%8 Dec 12
%V 145
%N 3
%@ 1521-7035
%G eng
%F Shen2012
%X Sjogren's syndrome (SS) is defined by autoantibodies to Ro and La. The current studies identified additional autoantibodies in SS to salivary gland protein 1 (SP-1), carbonic anhydrase 6 (CA6) and parotid secretory protein (PSP). These autoantibodies were present in two animal models for SS and occurred earlier in the course of the disease than antibodies to Ro or La. Patients with SS also produced antibodies to SP-1, CA6 and PSP. These antibodies were found in 45% of patients meeting the criteria for SS who lacked antibodies to Ro or La. Furthermore, in patients with idiopathic xerostomia and xerophthalmia for less than 2 years, 76% had antibodies to SP-1 and/or CA6 while only 31% had antibodies to Ro or La. Antibodies to SP-1, CA6 and PSP may be useful markers for identifying patients with SS at early stages of the disease or those that lack antibodies to either Ro or La.
%K Animals
%K Antibodies, Antinuclear
%K Autoantibodies
%K Autoantigens
%K Biomarkers
%K Carbonic Anhydrases
%K Case-Control Studies
%K Disease Models, Animal
%K Disease Progression
%K Female
%K Humans
%K Interleukins
%K Male
%K Mice
%K Mice, Inbred C57BL
%K Mice, Inbred NOD
%K Mice, Transgenic
%K Salivary Proteins and Peptides
%K Sjogren's Syndrome
%K Xerophthalmia
%K Xerostomia
%U http://dx.doi.org/10.1016/j.clim.2012.09.013
%U http://www.ncbi.nlm.nih.gov/pubmed/23123440
%P 251-255

PT Journal
AU Shen, L
   Suresh, L
   Lindemann, M
   Xuan, J
   Kowal, P
   Malyavantham, K
   Ambrus, JL
TI Novel autoantibodies in Sjogren's syndrome.
SO Clinical immunology (Orlando, Fla.)
JI Clin. Immunol.
PD Dec
PY 2012
BP 251
EP 255
VL 145
IS 3
DI 10.1016/j.clim.2012.09.013
LA eng
DE Animals; Antibodies, Antinuclear; Autoantibodies; Autoantigens; Biomarkers; Carbonic Anhydrases; Case-Control Studies; Disease Models, Animal; Disease Progression; Female; Humans; Interleukins; Male; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, Transgenic; Salivary Proteins and Peptides; Sjogren's Syndrome; Xerophthalmia; Xerostomia
AB Sjogren's syndrome (SS) is defined by autoantibodies to Ro and La. The current studies identified additional autoantibodies in SS to salivary gland protein 1 (SP-1), carbonic anhydrase 6 (CA6) and parotid secretory protein (PSP). These autoantibodies were present in two animal models for SS and occurred earlier in the course of the disease than antibodies to Ro or La. Patients with SS also produced antibodies to SP-1, CA6 and PSP. These antibodies were found in 45% of patients meeting the criteria for SS who lacked antibodies to Ro or La. Furthermore, in patients with idiopathic xerostomia and xerophthalmia for less than 2 years, 76% had antibodies to SP-1 and/or CA6 while only 31% had antibodies to Ro or La. Antibodies to SP-1, CA6 and PSP may be useful markers for identifying patients with SS at early stages of the disease or those that lack antibodies to either Ro or La.
ER

PMID- 23123440
OWN - NLM
STAT- MEDLINE
DA  - 20121119
DCOM- 20130117
LR  - 20151119
IS  - 1521-7035 (Electronic)
IS  - 1521-6616 (Linking)
VI  - 145
IP  - 3
DP  - 2012 Dec
TI  - Novel autoantibodies in Sjogren's syndrome.
PG  - 251-5
LID - 10.1016/j.clim.2012.09.013 [doi]
LID - S1521-6616(12)00239-2 [pii]
AB  - Sjogren's syndrome (SS) is defined by autoantibodies to Ro and La. The current
      studies identified additional autoantibodies in SS to salivary gland protein 1
      (SP-1), carbonic anhydrase 6 (CA6) and parotid secretory protein (PSP). These
      autoantibodies were present in two animal models for SS and occurred earlier in
      the course of the disease than antibodies to Ro or La. Patients with SS also
      produced antibodies to SP-1, CA6 and PSP. These antibodies were found in 45% of
      patients meeting the criteria for SS who lacked antibodies to Ro or La.
      Furthermore, in patients with idiopathic xerostomia and xerophthalmia for less
      than 2 years, 76% had antibodies to SP-1 and/or CA6 while only 31% had antibodies
      to Ro or La. Antibodies to SP-1, CA6 and PSP may be useful markers for
      identifying patients with SS at early stages of the disease or those that lack
      antibodies to either Ro or La.
CI  - Copyright (c) 2012 Elsevier Inc. All rights reserved.
FAU - Shen, Long
AU  - Shen L
AD  - Division of Allergy, Immunology and Rheumatology, Department of Medicine, School 
      of Medicine and Biomedical Sciences, State University of New York at Buffalo,
      Buffalo, NY 14203, USA.
FAU - Suresh, Lakshmanan
AU  - Suresh L
FAU - Lindemann, Matthew
AU  - Lindemann M
FAU - Xuan, Jingxiu
AU  - Xuan J
FAU - Kowal, Przemek
AU  - Kowal P
FAU - Malyavantham, Kishore
AU  - Malyavantham K
FAU - Ambrus, Julian L Jr
AU  - Ambrus JL Jr
LA  - eng
PT  - Journal Article
DEP - 20121012
PL  - United States
TA  - Clin Immunol
JT  - Clinical immunology (Orlando, Fla.)
JID - 100883537
RN  - 0 (Antibodies, Antinuclear)
RN  - 0 (Autoantibodies)
RN  - 0 (Autoantigens)
RN  - 0 (BPIFA2 protein, human)
RN  - 0 (Biomarkers)
RN  - 0 (Interleukins)
RN  - 0 (Psp protein, mouse)
RN  - 0 (SS-A antibodies)
RN  - 0 (SS-B antibodies)
RN  - 0 (Salivary Proteins and Peptides)
RN  - 0 (TXLNA protein, mouse)
RN  - EC 4.2.1.1 (Carbonic Anhydrases)
RN  - EC 4.2.1.1 (carbonic anhydrase VI)
SB  - IM
MH  - Animals
MH  - Antibodies, Antinuclear/blood
MH  - Autoantibodies/*blood
MH  - Autoantigens/immunology
MH  - Biomarkers/blood
MH  - Carbonic Anhydrases/immunology
MH  - Case-Control Studies
MH  - Disease Models, Animal
MH  - Disease Progression
MH  - Female
MH  - Humans
MH  - Interleukins/genetics/immunology
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Inbred NOD
MH  - Mice, Transgenic
MH  - Salivary Proteins and Peptides/immunology
MH  - Sjogren's Syndrome/etiology/*immunology
MH  - Xerophthalmia/immunology
MH  - Xerostomia/immunology
EDAT- 2012/11/06 06:00
MHDA- 2013/01/18 06:00
CRDT- 2012/11/06 06:00
PHST- 2012/04/21 [received]
PHST- 2012/09/26 [revised]
PHST- 2012/09/30 [accepted]
PHST- 2012/10/12 [aheadofprint]
AID - S1521-6616(12)00239-2 [pii]
AID - 10.1016/j.clim.2012.09.013 [doi]
PST - ppublish
SO  - Clin Immunol. 2012 Dec;145(3):251-5. doi: 10.1016/j.clim.2012.09.013. Epub 2012
      Oct 12.
TY  - JOUR
AU  - Shen, Long
AU  - Suresh, Lakshmanan
AU  - Lindemann, Matthew
AU  - Xuan, Jingxiu
AU  - Kowal, Przemek
AU  - Malyavantham, Kishore
AU  - Ambrus, Julian L.
PY  - 2012/Dec/12
TI  - Novel autoantibodies in Sjogren's syndrome.
T2  - Clin. Immunol.
JO  - Clinical immunology (Orlando, Fla.)
SP  - 251
EP  - 255
VL  - 145
IS  - 3
KW  - Animals
KW  - Antibodies, Antinuclear
KW  - Autoantibodies
KW  - Autoantigens
KW  - Biomarkers
KW  - Carbonic Anhydrases
KW  - Case-Control Studies
KW  - Disease Models, Animal
KW  - Disease Progression
KW  - Female
KW  - Humans
KW  - Interleukins
KW  - Male
KW  - Mice
KW  - Mice, Inbred C57BL
KW  - Mice, Inbred NOD
KW  - Mice, Transgenic
KW  - Salivary Proteins and Peptides
KW  - Sjogren's Syndrome
KW  - Xerophthalmia
KW  - Xerostomia
N2  - Sjogren's syndrome (SS) is defined by autoantibodies to Ro and La. The current studies identified additional autoantibodies in SS to salivary gland protein 1 (SP-1), carbonic anhydrase 6 (CA6) and parotid secretory protein (PSP). These autoantibodies were present in two animal models for SS and occurred earlier in the course of the disease than antibodies to Ro or La. Patients with SS also produced antibodies to SP-1, CA6 and PSP. These antibodies were found in 45% of patients meeting the criteria for SS who lacked antibodies to Ro or La. Furthermore, in patients with idiopathic xerostomia and xerophthalmia for less than 2 years, 76% had antibodies to SP-1 and/or CA6 while only 31% had antibodies to Ro or La. Antibodies to SP-1, CA6 and PSP may be useful markers for identifying patients with SS at early stages of the disease or those that lack antibodies to either Ro or La.
SN  - 1521-7035
UR  - http://dx.doi.org/10.1016/j.clim.2012.09.013
UR  - http://www.ncbi.nlm.nih.gov/pubmed/23123440
ID  - Shen2012
ER  - 
<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
<b:Source>
<b:Tag>Shen2012</b:Tag>
<b:SourceType>ArticleInAPeriodical</b:SourceType>
<b:Year>2012</b:Year>
<b:Month>Dec</b:Month>
<b:Day>12</b:Day>
<b:PeriodicalName>Clinical immunology (Orlando, Fla.)</b:PeriodicalName>
<b:Volume>145</b:Volume>
<b:Issue>3</b:Issue>
<b:Pages>251-255</b:Pages>
<b:Author>
<b:Author><b:NameList>
<b:Person><b:Last>Shen</b:Last><b:First>Long</b:First></b:Person>
<b:Person><b:Last>Suresh</b:Last><b:First>Lakshmanan</b:First></b:Person>
<b:Person><b:Last>Lindemann</b:Last><b:First>Matthew</b:First></b:Person>
<b:Person><b:Last>Xuan</b:Last><b:First>Jingxiu</b:First></b:Person>
<b:Person><b:Last>Kowal</b:Last><b:First>Przemek</b:First></b:Person>
<b:Person><b:Last>Malyavantham</b:Last><b:First>Kishore</b:First></b:Person>
<b:Person><b:Last>Ambrus</b:Last><b:First>Julian</b:First><b:Middle>L</b:Middle></b:Person>
</b:NameList></b:Author>
</b:Author>
<b:Title>Novel autoantibodies in Sjogren&apos;s syndrome.</b:Title>
 <b:ShortTitle>Clin. Immunol.</b:ShortTitle>
<b:Comments>Sjogren&apos;s syndrome (SS) is defined by autoantibodies to Ro and La. The current studies identified additional autoantibodies in SS to salivary gland protein 1 (SP-1), carbonic anhydrase 6 (CA6) and parotid secretory protein (PSP). These autoantibodies were present in two animal models for SS and occurred earlier in the course of the disease than antibodies to Ro or La. Patients with SS also produced antibodies to SP-1, CA6 and PSP. These antibodies were found in 45% of patients meeting the criteria for SS who lacked antibodies to Ro or La. Furthermore, in patients with idiopathic xerostomia and xerophthalmia for less than 2 years, 76% had antibodies to SP-1 and/or CA6 while only 31% had antibodies to Ro or La. Antibodies to SP-1, CA6 and PSP may be useful markers for identifying patients with SS at early stages of the disease or those that lack antibodies to either Ro or La.</b:Comments>
</b:Source>
</b:Sources>